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P21 CLINICAL AND LABORATORY STUDY OF CHRONIC MYELOID
LEUKAEMIA IN IRAQI KURDISTAN
M. Omar, A. Sheikha *. Hawler Medical University, Erbil, Iraq
Background: Chronic myeloid leukaemia (CML) is a clonal hae-
matopoietic stem-cell disorder. It was the first malignancy found
to be associated with a recurring chromosomal abnormality, Phil-
adelphia chromosome, resulting from translocation of genetic
material from one chromosome to another to form a fusion gene
(BCR/ABL). CML was the first disease in which the fusion gene was
recognised as giving rise to an abnormal fusion protein, funda-
mental in the pathogenesis of the disease. It is now the first dis-
order for which a therapeutic agent, imatinib mesylate (Glivec),
has been designed to specifically target the molecular defect, with
potential for cure.
Methods: This descriptive study was done at Nanakaly and
Hiwa hospitals in Erbil and Sulaimaniya, Iraq, from December 1,
2008, to June 30, 2009. A total of 100 patients with CML were ran-
domly selected. Clinical examination and laboratory investiga-
tions were done for all patients. Results were subjected to the
international Sokal scoring system and compared with other
studies.
Findings: The mean age of the study group was 42.8 ± 13.23
years (range 15–87). The male-to-female ratio was 1:1.08. The
most common symptoms at onset were fatigue, weight loss,
and abdominal fullness. At presentation, the mean white-cell
count was 164,000/lL, and the mean percentage of blast cells
was 3% in peripheral blood and 4% in marrow. Presence of the
Philadelphia chromosome and BCR/ABL gene was available for
18 cases and was positive for all. According to the International
Sokal Scoring System, patients were divided into three groups:
group A patients with good prognosis (91%), group B with moder-
ate prognosis (7%), and group C with poor prognosis (2%).
Interpretation: The mean age at presentation for CML in this
study was lower than in developed countries. Significant prognos-
tic indicators were platelet count, and peripheral and marrow
blast-cell percentage; a high count and high percentages were
associated with poor prognosis.
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P22 OLFACTORY NEUROBLASTOMA – RAMATHIBODI HOSPITAL
EXPERIENCE
S. Chompoonuch, E. Sirachainan *. Oncology Unit, Department of
Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Background: Olfactory neuroblastoma, also known as esthesio-
neuroblastoma, is a rare malignant tumour of the nasal cavity.
Diagnosis can be difficult and the disease can mimic other types
of sinonasal tract tumours. There has been only one case report
of this disease in Thai patients.
Methods: Olfactory neuroblastoma patients who were treated
at Ramathibodi Hospital from January, 2000, to October, 2010,
were identified and reviewed.
Findings: Nine patients medical records were reviewed; six
(66.7%) of the patients were male. Median age was 53 years (range
30–68) with peak incidence of olfactory neuroblastoma in the
sixth decade. The mean duration of symptoms prior to diagnosis
was 6.8 months (2–24). The most common presenting symptoms
were nasal obstruction (55%) and orbital symptoms (44%). 66% of
patients had Kadish stage C disease and the rest had stage B. One-
third of patients had nodal metastases initially, and all had locally
advanced disease. Four patients were initially misdiagnosed as
having undifferentiated or poorly differentiated carcinoma. Sur-
gery was done upfront in seven patients; five underwent postop-
erative radiotherapy. Chemotherapy as primary treatment was
given to two patients. With a median follow-up of 42 months
(5–115), the median overall survival of Kadish B patients was sig-
nificantly longer than Kadish C patients (not reached vs. 12.3
months, respectively; p = 0.04). None of patients with initial nodal
metastases survived longer than 13 months.
Interpretation: A high index of suspicion, especially in nasal
cavity tumours, and proper immunohistochemistry are essential
in the diagnosis of olfactory neuroblastoma. Kadish staging is
useful as a prognostic factor. Patients who presented with nodal
metastasis had very poor prognosis. A multidisciplinary team
approach may improve treatment outcome.
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P23 MANAGEMENT OF PATIENTS WITH NEGATIVE HEPATITIS B
SURFACE ANTIGEN AND POSITIVE ANTI-HEPATITIS B CORE
ANTIBODY UNDERGOING CHEMOTHERAPY FOR MALIGNANT
LYMPHOMA
Y. Lau *, W. Cheung, T. Chau, K. Leung, Y. Lam, S. Lin. United
Christian Hospital, Hong Kong, China
Background: A substantial proportion of patients with negative
hepatitis B surface antigen (HBsAg) and positive anti-hepatitis B
core antibody (anti-HBcAb) have acute hepatitis after
chemotherapy.
Methods: Patients with negative HBsAg and positive anti-
HBcAb undergoing intensive chemotherapy for malignant lym-
phoma were recruited from 2007 to 2009. Hepatitis B virus DNA
was checked every 4 weeks during chemotherapy and every 8
weeks after completion of chemotherapy, for 1 year.
Findings: 20 patients were recruited. 13 patients had diffuse
large B-cell lymphoma. Three patients had Burkitt or Burkitt-like
lymphoma. Two patients had T-cell lymphoma and two had
another histological type. Mean age was 69 years (range 44–86).
Seven patients had stage I–II disease and 13 patients had stage
III–IV disease. Two patients died of primary refractory disease in
less than 1 year, without evidence of acute hepatitis. Three
patients who had a flare-up of acute hepatitis B were successfully
identified, and all recovered after anti-viral treatment, without
development of liver failure.
Interpretation: 16.6% of lymphoma patients with negative
HBsAg and positive anti-HBcAb had a flare-up of hepatitis B after
chemotherapy. Monitoring of hepatitis-B virus DNA every 4 weeks
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during chemotherapy and 8-weekly after chemotherapy success-
fully identified all cases of acute hepatitis B.
Funding: GlaxoSmithKline provided the funding for monitoring
of hepatitis B virus DNA.
The authors declared no conflicts of interest.
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P24 SINGLE INSTITUTION EXPERIENCE OF ODONTOGENIC CYST
AND TUMOURS, AND TUMOUR-LIKE LESIONS OF THE JAW, IN
SOUTH KERALA – A 10-YEAR CLINICOPATHOLOGICAL SURVEY
P.S. Satheeshkumar *, A. Balan. Department of Oral Medicine and
Radiology, Government Dental College, Trivandrum, Kerala, India
Background: This study aimed to evaluate and compare the rel-
ative frequency, distribution, sites of presentation, and radiologi-
cal and histological variations of odontogenic cysts, tumours, and
tumour-like lesions in cases reported to the Government Dental
College, Trivandrum, India.
Methods: A retrospective analysis was done on 3222 biopsy
cases reported to the Department of Oral Medicine and Radiology
from January, 2000, to May, 2009. Biopsy records were also evalu-
ated from the Department of Oral Medicine and Department of
Oral Pathology and Microbiology.
Findings: Of 3222 biopsy cases reported, 1082 were diagnosed as
odontogenic cysts and tumours, and tumour-like lesionsof the jaw.
Of the 1082 cases, the highest frequencies were as follows: cyst of
inflammatory origin (periapical and radicular cyst; n = 589,
54.4%); ameloblastoma (n = 141, 13.03%); dentigerous cyst (n = 98,
9.05%); keratinising odontogenic tumour (n = 74, 6%); fibrous dys-
plasia (n = 25, 2%; females = 19, 75%; males = 6, 24%); dentigerous
cyst showing ameloblastoma transformation (n = 24, 2%); eruption
cyst (n = 55, 5%); osteoma (n = 22, 2%); central ossifying fibroma
(n = 20, 1.8%; females = 13, 65%; males = 7, 35%); odontome
(n = 16, 1.4%); adenomatoid odontogenic tumour (n = 6, 0.5%); cen-
tral giant-cell granuloma (n = 9, 0.8%); central odontogenic fibroma
(n = 6, 0.5%); cementoblastoma (n = 8, 0.8%); Pindborg tumour
(n = 5, 0.4%); and benign fibrous histiocytoma (n = 3, 0.2%). Rarer
conditions,which accounted for less than 0.2% of cases, were juve-
nile ossifying fibroma, ameloblastic fibrodontoma, chondrosar-
coma, central odontogenic myxoma, and plasma-cell myeloma.
Interpretation: The relative frequencies and sites of presenta-
tion of odontogenic cysts, tumours, and tumour-like lesions of
the jaw in different geographic backgrounds are essential for
early diagnosis and management of these potentially destructive
benign lesions.
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P25 IMPACT OF CONTRIBUTION BY ONCOLOGY PHARMACISTS
ON LYMPHOMAWARD ROUNDS
J. Chiang *, K. Tay, V. Shih, R. Quek, ST. Lim, M. Tao,
A. Chan. National Cancer Centre, Singapore
Background: In the oncology setting, specialist multidisciplin-
ary teams are often needed to ensure that patients receive the
best possible care and treatment. As drug experts, pharmacists
manage chemotherapy-related and supportive care issues. They
can also help to manage treatment costs and facilitate accurate
prescribing to maximise patient safety. Documentation of inter-
ventions done by pharmacists on ward rounds can be clinically
and educationally useful for improving prescribing safety and
pharmacy services. This study evaluated the impact of interven-
tions made by pharmacists on lymphoma ward rounds.
Methods: This was a cross-sectional analysis of interventions
made by pharmacists on the lymphoma service from 2009 to
2010, at Singapore General Hospital, where pharmacists from the
National Cancer Centre Singapore join lymphoma ward rounds 5
days a week. Interventions were documented in a database and
were given an impact rating by two independent reviewers – a lym-
phoma oncologist and an oncology pharmacist. Interventions
were classified into four impact levels and assessed as drug-
related, cost-related, or workflow issues. Spearmans correlation
test was used to test for agreement between the two reviewers.
Findings: A total of 295 interventions were made for 116
patients; 97% were accepted by oncologists. Most interventions
were related to antimicrobial dosing or usage (35%) and chemo-
therapy-related issues (29%). 23% of impact ratings were level 3
or 4. Ratings of interventions that helped to avoid or solve drug-
related problems and improve workflow were moderately concor-
dant between the two reviewers, in the areas of supportive care
(p = 0.544) and chemotherapy-related issues (p = 0.559). Overall,
the oncologist gave higher ratings for cost-saving interventions
and the pharmacist gave higher ratings for interventions that
help to avoid or resolve drug-related problems and improve
workflow.
Interpretation: Interventions by oncology pharmacists are well-
accepted onward rounds andhave a positive effect on patient care.
Funding: None.
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P26 EXPRESSION OF MAGE-A3 AND ITS PROGNOSTIC VALUE IN
HEPATOCELLULAR CARCINOMA IN ASIAN PATIENTS
P. Lee a,*, T. Tanwandee b, A. Chotirosniramit c, D. DAgostino d,
J. Louahed d, A. Myo e, P. Therasse d. a National Taiwan University
Hospital, Taipei, Taiwan. b Siriraj Hospital, Mahidol University,
Bangkok, Thailand. c Maharajnakorn Chiang Mai Hospital,
ChiangMai, Thailand. d GlaxoSmithKline Biologicals, Rixensart,
Belgium. e GlaxoSmithKline Biologicals, Singapore
Background: The MAGE-A3 tumour-specific antigen is
expressed by many tumours, including hepatocellular carcinoma
(HCC), and is therefore an appropriate target for active immuno-
therapy. Here, we report results from a retrospective epidemiolog-
ical evaluation of MAGE-A3 gene expression in Asian patients
with pathologically proven HCC, and its prognostic value.
Methods: 200 samples were analysed from two centres in Thai-
land and one in Taiwan. Patient and tumour characteristics were
also collected. Formalin-fixed paraffin-embedded (FFPE) tumour
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